Single-injection, HA Product Gets FDA OK for Knee OA Pain
More than 20 million Americans are afflicted with knee osteoarthritis and there is no cure.
Officials with Bioventus announced in a press release today that they have received US FDA approval for their single-injection, hyaluronic acid (HA) product (Durolane) used for joint lubrication in the treatment of pain associated with knee osteoarthritis (OA).1
Durolane will complement the company’s OA portfolio, which includes 3-injection HA GELSYN-3 and the 5-injection HA SUPARTZ FX. Bioventus markets and sells Durolane in more than 25 countries including Canada, Mexico, Australia, and throughout much of Europe, and the product will launch in the US in early 2018.
“More than 20 million Americans are afflicted with knee osteoarthritis and there is no cure, but the associated pain can be managed,” Tony Bihl, CEO of Bioventus said in the press release. “Durolane has been a proven knee OA pain reliever for more than 15 years, improving the lives of more than 1 million people worldwide. It will join our current offerings to provide even more efficacious treatment options for US patients, physicians and payers.”
Reference
Bioventus Receives US FDA Approval for Durolane [news release]. Durham, NC. Bioventus Global website; Sept. 5, 2017. https://www.bioventusglobal.com/bioventus-receives-us-fda-approval-durolane/ Accessed Sept. 5, 2017.
